320 W 10th Ave
A343 Starling Loving Hall
Columbus, OH 43210
Phone: (614) 293-3507
Associate Professor-Clinical, Hematology
Director-00, CHRI Administration
How to implement process and system changes to improve quality and safety
Increase awareness of "Patient and Family Centered Care"
Fungal infections in immunocompromised hosts
Pharmacy Partnership and Collaboration: The high risk of chemotherapy makes it imperative that we have multiple checks and balances with chemotherapy ordering and administration. We have stream lined the clinic flow as it relates to chemotherapy administration. I have been one of the driving forces to get pharmacists on the inpatient services and ambulatory sites in which chemotherapy is given. I have been directly involved with interviewing and hiring of pharmacists to staff the inpatient as well as ambulatory sites so as to increase patient safety and education regarding chemotherapy agents. We have hired a James Medication Safety Pharmacist and this person reports to me as well as pharmacy. We have a robust process by which we evaluate all medication events in our event reporting system. In addition, I have been involved with multiple other quality improvement projects with pharmacy as it relates to nausea/vomiting, anemia management, patient medication assistance program, DVT prophylaxis, and chemotherapy OK to treat project.
Quality Collaboration: Our quality program has a great working relationship with the University Quality program as evidenced by our teamwork and improvements in our overall Harm scorecard, root cause analysis of sentinel events, and alignment of quality initiatives. Our collaboration with contracted services is best evidenced by the Febrile Neutopenia/Code Sepsis project in our ED by which our patients now get antibiotics delivered in a more timely manner and is now best in class.
Collaboration with our IT department: I have been intimately involved with all electronic system selection, integration, education, and implementation in The James. I was actively involved with the Beacon Oncology module from inception. I went to EPIC headquarters for training to be a super-user.
Referring Physician Partnership: I have an extensive referral base and continue to be the major point person of contact for the sickest or most complex BMT referral patients. I have earned the respect and trust of the referring physicians and have an excellent relationship with them. Because of our rapid growth and addition of multiple faculty, they often will call me and ask about the competency of one of my colleagues. Likewise, if they have any complaints about a specific physician at the James, I am the first to be contacted.
Research Collaboration: Our Quality program has an active partnership with the Clinical Trial Office. We have many quality improvement clinical trial projects and we assure that there is always a major research related James Quality initiative each year. A few initiatives include: Identification of patients on clinical trial, Chemotherapy Clearance plan, OK to treat, Toxicity Assessment, and high volume clinical trial initiation. On a personal basis, I am involved with two cardiology research protocols requiring bone marrow harvesting. Studies would not have been able to open without my involvement.
8/1/1995: Assistant Professor of Clinical Internal Medicine
7/1/2001: Associate Professor of Clinical Internal Medicine.
I joined the Bone Marrow Transplant (BMT) program at OSU in 1995 as an Assistant Professor in the clinical track. I enjoyed the clinical duties and teaching of the medical students/residents and at that time and was set on the path to become a clinician educator. Since that time, I have developed an extensive referral base and have acquired 18 years of sub-specialized BMT expertise. My unique procedural skills have resulted in me performing nearly 100% of all surgical bone marrow harvests. My clinical expertise is with the management of patients with acute and chronic Graft Vs Host Disease (GVHD). GVHD is a complex and difficult condition to treat and involves using high levels of immunosuppressive medications that puts the patient at high risk for opportunistic infections. My expertise in managing these infections led to my appointment of Chair of the Infection Control committee for 10 years.
However, after my Promotion to Associate Professor in 2001, my career took on a major shift in focus. I was asked to take on more of an administrative/ leadership role. The James was growing by leaps and bounds (increasing patient volume by 30% yearly) and Dr. Caligiuri asked me to oversee this expansion. I was made Medical Director of Outpatient Services for The James in 2001. I was responsible for the clinic expansion projects for 2 James, Stoneridge, Martha Morehouse, Clinical Trials Unit, and ICC (Immediate Care Center). My job was to accommodate the rapid growth and assure clinical standardization and efficiencies. It was through my innovative ideas and leadership that the Medication Assistance Program, auto-faxing of progress notes to referring physicians, pharmacy directed nausea/vomiting as well as anemia management programs were developed. During this time I not only made major contributions to the scholarship of practice but also to the financial bottom line for The James as well as Wexner Medical Center. My innovative formation of the Medication Assistance Program alone has led to savings for The James totaling >59 million dollars in written off expenses. I was also the James physician lead for the entire process of electronic medical record (EMR) selection, education, and implementation. In the process of our converting to an outpatient EMR, The James had no reduction in physician productivity. This was a feat that many other sites could not achieve. Surely, I did not accomplish this on my own but the results achieved did not occur by chance either but from detailed planning, excellent communication, and strong leadership.
In 2008, I was asked to become Medical Director of Quality for The James. Under my leadership, we have made numerous process and system improvements to improve Quality and Patient Safety. Two national metrics to exhibit our success is by the awarding of the Leapfrog Quality award to The James for the past 4 consecutive years. This is a prestigious national recognition to hospitals for exceptional quality and patient safety. We are one of two cancer hospitals in the nation to have earned this distinction. In addition, The OSU Wexner Medical Center was honored in 2013 with the UHC Quality Leadership Award which puts us as among the top ten academic medical centers in the nation. This award from University HealthSystem Consortium (UHC) is especially important because it honors those outstanding performers at the top of its annual Quality and Accountability Study. This report ranks hospital systems based on publicly reported data for our Medical Center's performance in the areas of mortality, effectiveness, safety, equity, patient-centeredness and efficiency.
My scholarship of practice is grounded in our tripart mission—excellence in patient care, teaching, and research: with excellence in patient care being the crucial element for the success of our other two missions. I have excelled in all three missions with having obtained successful clear-cut metrics for teaching (College of Medicine Professor of the Year 2002, Bertha Bouroncle Teaching Award, and Internal Medicine Clerkship Teaching Award) as well as multiple years of regional and national recognition for exceptional patient care (America's Best Doctors, America's Top Physicians U.S News and World Report). Research in The James is a major focus. I actively participate in numerous clinical trials. Administratively, our quality program has done multiple clinical trial projects that have improved access, efficiency, documentation, and quality and patient safety of patients on clinical trials.
Early in my academic career my focus was on the individual patient. It now revolves around the system and process improvements that help provide the best care for all of our patients. Through my leadership and administrative responsibilities I have made numerous and major scholarship of practice contributions as it relates to: curriculum development, practice guidelines, standard operating procedures, improved transparency, professionalism, improved Quality and Patient Safety as well as increased efficiencies, resource utilization, and profitability to The James as well as Wexner Medical Center.
To recap, since my last promotion in 2001, I have had two administrative positions, Medical Director of Outpatient Services (2001) and Medical Director of Quality (2008). Despite a 50% administrative position I still perform nearly 100% inpatient clinical duties as per my own request. I have earned the trust and respect of my peers because I have led by example. I am committed to making The James/ OSU Wexner Medical Center go from excellence to eminence and become one of the safest hospitals in the nation. My leadership and scholarly practice has resulted in innovative and impactful improvements in system and processes for the betterment of patient care/quality/safety.
I was the invited guest speaker for a fund raising event to raise money and awareness for the Bone Marrow Transplant Unit Family Fund. The event was called Art for the Heart. Numerous artists, vendors, and volunteers donated a wide variety of collected art pieces and these were auctioned off at this event. The event occurred on October 27th, of 2006. NBC 4 anchor Amy Basista was mistress of ceremonies. The event was a huge success.
2001-Present: James Medication Assistance Program. I was directly involved with the concept, implementation, and structure of this program in direct collaboration with Pharmacy. We had patients that were denied best supportive treatments for their malignancies due to lack of financial coverage/insurance. The James would provide these medications and would be absorbing the expense at > $50,000 in write-offs per month. I worked with pharmacy to develop a program in which the pharmaceutical companies would help patients get free drug if they could not afford it. The program was initially started with the pharmaceutical companies in which I had direct contact but soon expanded to include any pharmaceutical company that was willing to support patients that had financial constraints. We were able to start this program within 6 months of my medical director of outpatient services appointment. In the next 6 months we provided $677,000 of medication assistance. From Dec 2001 to June 2012 the James has helped 3390 patients, processed 10,587 applications and accessed medications valued at $59,331,964.40. Our program was so successful that pharmacy extended the program to include the University Hospital in 3/1/2004. The total amount for the Patient Assistance Program for the entire OSUWMC has totaled more than 107 million dollars as of 6/2012. The Medication Assistance Program conceptually began in The James under my leadership and has flourished under Pharmacy’s management.
2001-2008: Developed a Pharmacist Directed Anemia Management and Antiemetic programs. This involved the conceptual management of these conditions by pharmacists rather than physicians. There was initial concern by many of the physicians that the pharmacists would not have the knowledge to undertake this task. We developed a detailed algorithm that would specifically spell out what would have to be done on every patient presenting with anemia and if the patient did not exactly fall into a specific pathway the pharmacist would have to contact the physician. The Pharmacist Directed Anemia management program was so successful that it paved the way for easy implementation for the Pharmacy-Directed Anti-emetic program. The chemotherapy regimens were easily split up into low, moderate, and highly emetogenic regimens and the pharmacist would adjust the supportive anti-emetics accordingly. This enabled the physicians to focus on the chemotherapy ordering and leave the supportive measures to pharmacy. This was very helpful when we transitioned into an electronic medical record and computer ordering process, for it was very easy to make order sets that would now incorporate the chemotherapy and supportive therapies into one standard order set.
2009-Present: EOL (End of Life) -AIP (Advanced Illness Pathway): The James does not have an inpatient Hospice program. We wished to implement a multidisciplinary standardized pathway that would address the needs of the dying patient, family, as well as health care providers. The pathway was initially called the End of Life Pathway. The success of the pathway led to adoption across the Medical Center and the name was changed to the AIP. I was involved in the initial selection of pilot site, charter, content design, education roll-out to the physicians, IHIS order content, and follow-up metrics. Enrollment of patients to this pathway was a James Board Goal initiative in 2012.
2008-present: Innovation regarding culture change with increased transparency in organization: I have been one of the moving forces behind increasing transparency. The James Quality and Patient Safety Committee was the first quality meeting to have a Patient Family Advisor on its membership. This was innovative and has lead to the adoption elsewhere in our medical center. We also meet regularly with members of the James Board to discuss quality issues in greater detail than previously done. The entire Medical Center is starting to embrace the culture of increased transparency and it started in The James.
2010-Present: Celebration of Quality Success. The James was the first to have a quality fair to celebrate the successes of our accomplishments. We would have posters of the various DMAIC projects and would give prizes for the best in class. Our patient and family advisor program would always have the center of the room under the main tent and be the major focus. The turnout was outstanding and staff appreciated the effort.
I have taught over 70 fellows since my last promotion and over 100 fellows since my initial hire. I have mentored these fellows while on inpatient services for Heme or BMT. I have also had numerous encounters with them at various required education meetings during their fellowship: Journal Club, Fellowship Lecture Series, Tumor Board, Lymphoma Conference, BMT Census Meeting, Fellowship Board Review Meeting, and Mortality and Morbidity Conference. I have given career advise to many of these fellows, particularly to those that have stayed here at The James but also to those that have gone to other academic places or private practice.
Hamadani Mehdi 7/1/06-6/30/09 was one of our fellows that I had particular influence/contact during his fellowship. He has chosen a career in BMT. I continue to have correspondence with him and collaborate on clinical trials.
Kindwall-Keller Tamila 7/1/01-6/30/04 was one of my fellows that was assigned to me in my continuity clinic. She is currently a BMT physician at the University Hospitals in Cleveland. I have mentored her and given her career advice over the years.
Nicole Rich,, Jan 2009 Matthew Potter,, Jan 2009 Jacqueline Vanderburgh,, Jan 2009 Jonathan Gardner,, Jan 2009 Daniel Rabe,, Mar 2008 Diane Song,, Sep 2005 Michael Shirley,, Sep 2005
I have given numerous grand rounds or CME related presentations as it relates to risk factors for fungal infections, prevention/management of febrile neutropenia, identification and treatment of sepsis, anemia management, chemotherapy induced nausea management, various topics about Bone Marrow transplantation, Myeloma, CLL, AML, ALL, Hodgkin's and Non Hodgkin's lymphoma. I have always received great reviews.
2001-2008: Developed a Pharmacist Directed Anemia Management and Anti-emetic programs. This involved the conceptual management of these conditions by pharmacists rather than physicians. There was initial concern by many of the physicians that the pharmacists would not have the knowledge to undertake this task. We developed a detailed algorithm that would specifically spell out what would have to be done on every patient presenting with anemia and if the patient did not exactly fall into a specific pathway the pharmacist would have to contact the physician. The Pharmacist Directed Anemia management program was so successful that it paved the way for easy implementation for the Pharmacy-Directed Anti-emetic program. The chemotherapy regimens were easily split up into low, moderate, and highly emetogenic regimens and the pharmacist would adjust the supportive anti-emetics accordingly. This enabled the physicians to focus on the chemotherapy ordering and leave the supportive measures to pharmacy. This was very helpful when we transitioned into an electronic medical record and computer ordering process, for it was very easy to make order sets that would now incorporate the chemotherapy and supportive therapies into one standard order set.
|2005 - present||Diane Song The Ohio State University.|
|2005 - present||Michael Shirley The Ohio State University.|
|2008 - present||Daniel Rabe The Ohio State University.|
|2009 - present||Nicole Rich The Ohio State University. Graduated 2009.|
|2009 - present||Matthew Potter The Ohio State University.|
|2009 - present||Jacqueline Vanderburgh The Ohio State University.|
|2009 - present||Jonathan Gardner The Ohio State University.|
|2011 - present||Ohio State University College of Medicine.|
|1991 - present||State of Ohio Medical License: State Medical Board of Ohio|
|1992 - present||Board Certification: American Board of Internal Medicine|
|1995 - present||Board Certification: American Board of Internal Medicine|
|1996 - present||Board Certification: American Board of Internal Medicine|
Copelan, E.A and Penza, S.L.. "Allogeneic Bone Marrow Transplantation: Should All Adults Patients with Acute Lymphoblastic Leukemia Undergo Allogeneic Bone Transplant?." In Current Controversies in Bone Marrow/Stem Cell Transplantation. -. Columbus: Humana Press, January 2000.
Copelan, E.A and Penza, S.L.. "Preparative Regimens." In Hematology: Basic Principles and Practice. -. Columbus: Churchill Livingstone, January 2000.
|04/01/2007 - 12/01/2009||HNP Service (The James Cancer Hospital)|
|04/01/2007 - 04/01/2011||Hematology 1 Inpatient Service (The James Cancer Hospital)|
|12/01/2010 - 03/01/2013||Hematology 3 Inpatient Service (The James Cancer Hospital)|
|01/01/2004 - 10/01/2013||Outpatient Service; Clinic (The James Cancer Hospital)|
|06/01/2004 - 10/01/2013||Bone Marrow Transplant Inpatient Service (The James Cancer Hospital)|
Moss TJ, Lazarus HM, Weaver CH, Buckner CD, Noga S, Preti R, Copelan E, Penza S, Cooper BW, Meagher RC, Herzig RH, Kahn DG, Prilutskaya M, Rosenfeld C, Pecora AL. "The clinical significance of breast cancer cells in marrow and stem cell products taken from stage IV patients." In Autologous Blood and Marrown Transplantation. Proceedings of the 9th International Symposium. (January 1999). 265-273.
|1982||B.S., Youngstown State University|
|1985||M.S., Youngstown State University|
|1989||M.D., The Ohio State University|
|1989||Alpha Omega Alpha. Alpha Omega Alpha.|
|1992||Diplomat, Internal Medicine. American Board of Internal Medicine.|
|1992||Thomas G Skillman House Staff Award of Excellence. College of Medicine.|
|1994||Clinical Fellowship. American Cancer Society.|
|1995||Diplomat, Medical Oncology. American Board of Internal Medicine.|
|1996||Diplomat, Hematology. American Board of Internal Medicine.|
|2001 - present||Bertha Bouroncle Teaching Award. Division of Hematology Highest Award for Fellowship Teaching.|
|2001 - present||Life Member. National Registry of Who's Who.|
|2002 - present||Professor of the Year. College of Medicine Graduating Class of 2002.|
|2004 - 2006||America's Top Physicians. Consumer Research Council of America.|
|2005 - present||The Top Doctor's in Central Ohio. Columbus Magazine.|
|2005||America's Best Doctors.|
|2007 - present||America's Best Doctors. U.S. News & World Report.|
|2007 - 2011||Best Doctors in Columbus. Columbus Monthly.|
|2009 - 2010||Internal Medicine Clerkship Teaching Award. Internal Medicine.|
|2009 - 2010||Highest Patient Satisfaction Award. Ohio State University Medical Center.|
Styler MJ; Crilley P; Biggs J; Moul J; Copelan E; Topolsky D; Avalos B; Penza S; Sabol P; Downs K; Szer J; Brodsky I; Marks DI. "Hepatic dysfunction following busulfan and cyclophosphamide myeloablation: a retrospective, multicenter analysis.." Bone marrow transplantation. Vol. 18, no. 1. (July 1996.): 171-176.
Copelan EA; Penza SL; Elder PJ; Belt PS; Scholl MD; Hehmeyer DM; Ezzone SA; Bechtel TP; Avalos BR. "Influence of graft-versus-host disease on outcome following allogeneic transplantation with radiation-free preparative therapy in patients with advanced leukemia.." Bone marrow transplantation. Vol. 18, no. 5. (November 1996.): 907-911.
Copelan EA; Ceselski SK; Ezzone SA; Lasky LC; Penza SL; Bechtel TP; Klein JL; Hehmeyer DM; Scholl MD; Marshall DD; Elder PJ; Risley GL; Avalos BR. "Mobilization of peripheral-blood progenitor cells with high-dose etoposide and granulocyte colony-stimulating factor in patients with breast cancer, non-hodgkin's lymphoma, and Hodgkin's disease." Journal of Clinical Oncology. Vol. 15, no. 2. (February 1997.): 759-765.
Copelan EA; Penza SL; Theil KS; Elder PJ; Bechtel TP; Tighe MB; Ezzone SA; Scholl MD; Belt PS; Young DC; Avalos BR. "The influence of early transplantation, age, GVHD prevention regimen, and other factors on outcome of allogeneic transplantation for CML following BuCy.." Bone marrow transplantation. Vol. 26, no. 10. (November 2000.): 1037-1043.
Copelan EA; Penza SL; Pohlman B; Avalos BR; Goormastic M; Andresen SW; Kalaycio M; Bechtel TP; Scholl MD; Elder PJ; Ezzone SA; O'Donnell LC; Tighe MB; Risley GL; Young DC; Bolwell BJ. "Autotransplantation following busulfan, etoposide and cyclophosphamide in patients with non-Hodgkin's lymphoma.." Bone marrow transplantation. Vol. 25, no. 12. (June 2000.): 1243-1248.
Copelan EA; Penza SL; Elder PJ; Ezzone SA; Scholl MD; Bechtel TP; Belt PS; Avalos BR. "Analysis of prognostic factors for allogeneic marrow transplantation following busulfan and cyclophosphamide in myelodysplastic syndrome and after leukemic transformation.." Bone marrow transplantation. Vol. 25, no. 12. (June 2000.): 1219-1222.
Copelan EA; Bechtel TP; Avalos BR; Elder PJ; Ezzone SA; Scholl MD; Penza SL. "Busulfan levels are influenced by prior treatment and are associated with hepatic veno-occlusive disease and early mortality but not with delayed complications following marrow transplantation." Bone Marrow Transplantation. Vol. 27, no. 11. (June 2001.): 1121-1124.
Abdelsayed, Rafik, A; Sumner, Ty; Allen, Carl, M; Treadway, Antwan; Ness, Gregory, M; Penza, Sam L. "Oral precancerous and malignant lesions associated with graft-versus-host disease: report of 2 cases.." Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics. Vol. 1, (January 2002.): 75-80.
Lin TS; Avalos BR; Penza SL; Marcucci G; Elder PJ; Copelan EA. "Second autologous stem cell transplant for multiply relapsed Hodgkin's disease." Bone Marrow Transplantation. Vol. 29, no. 9. (May 2002.): 763-767.
Farag SS; Elder PJ; Marcucci G; Penza S; Mrozek E; Molina A; Lin T; Avalos BR; Copelan E. "Radiation-free regimens result in similar outcomes of allogeneic hematopoietic progenitor cell transplantation in patients aged >or=50 years compared to younger adults with low-risk disease.." Bone marrow transplantation. Vol. 31, no. 2. (January 2003.): 87-93.
Copelan E; Hoshaw-Woodard S; Elder P; Penza S; Farag S; Marcucci G; Lin T; Ezzone S; Scholl MD; Bechtel T; Lemeshow S; Avalos B. "Therapy-related myelodysplasia and leukemia occur infrequently following Vp-16 priming and autotransplantation without total body irradiation." Bone Marrow Transplantation. Vol. 34, no. 1. (July 2004.): 85-87.
Lin TS; Penza SL; Avalos BR; Lucarelli MR; Farag SS; Byrd JC; Copelan EA.. "Diffuse alveolar hemorrhage following gemtuzumab ozogamicin." Bone Marrow Transplantation. Vol. 35, no. 8. (April 2005.): 823-824.
Farag SS; Bolwell BJ; Elder PJ; Kalaycio M; Lin T; Pohlman B; Penza S; Marcucci G; Blum W; Sobecks R; Avalos BR; Byrd JC; Copelan E. "High-dose busulfan, cyclophosphamide, and etoposide does not improve outcome of allogeneic stem cell transplantation compared to BuCy2 in patients with acute myeloid leukemia.." Bone marrow transplantation. Vol. 35, no. 7. (April 2005.): 653-661.
Littleton R; Penza SL; Avalos BR; Copelan EA. "Syngeneic vs. allotransplantation in chronic myeloid leukemia: all's well that ends well.." Transplantation. Vol. 80, no. 3. (August 2005.): 426-427.
Lauria G, Majorana A, Borgna M, Lombardi R, Penza S, Padovani A, Sapelli P. "Trigeminal small-fiber sensory neuropathy causes burning mouth syndrome." Pain. Vol. 115, no. 3. (June 2005.): 332-337.
Wadehra N; Farag S; Bolwell B; Elder P; Penza S; Kalaycio M; Avalos B; Pohlman B; Marcucci G; Sobecks R; Lin T; Andresen S; Copelan E. "Long-term outcome of Hodgkin disease patients following high-dose busulfan, etoposide, cyclophosphamide, and autologous stem cell transplantation.." Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. Vol. 12, no. 12. (December 2006.): 1343-1349.
Blum W; Bolwell BJ; Phillips G; Farag SS; Lin TS; Avalos BR; Penza SL; Marcucci G; Byrd JC; Kalaycio ME; Sobecks RM; Pohlman B; Brown S; Elder PJ; Copelan EA. "High disease burden is associated with poor outcomes for patients with acute myeloid leukemia not in remission who undergo unrelated donor cell transplantation.." Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. Vol. 12, no. 1. (January 2006.): 61-67.
Benson DM; Elder PJ; Lin TS; Blum W; Penza S; Avalos B; Copelan E; Farag SS. "High-dose melphalan versus busulfan, cyclophosphamide, and etoposide as preparative regimens for autologous stem cell transplantation in patients with multiple myeloma.." Leuk Res. Vol. 31, no. 8. (August 2007.): 1069-1075.
Griffith N, Allen C, Penza S, Pultz A. "The Impact of the Long-Acting Erythropoiesis Stimulating Protien (ESP) on Patient Throughput in a Hospital-Based Ambulatory Oncology Clinic." Hospital Pharm. Vol. 43, no. 5. (May 2008.): 388-95.
Hamadani M; Hofmeister CC; Jansak B; Phillips G; Elder P; Blum W; Penza S; Lin TS; Klisovic R; Marcucci G; Farag SS; Devine SM. "Addition of infliximab to standard acute graft-versus-host disease prophylaxis following allogeneic peripheral blood cell transplantation.." Biol Blood and MarrowTransplant. Vol. 14, no. 7. (July 2008.): 783-789.
Hamandani M, Blum W, Phillips G, Elder P, Andritsos L, Hofmeister C, O'Donnell L, Klisovic R, Penza S, Garzon R, Krugh D, Lin T, Bechtel T, Benson DM, Byrd JC, Marcucci G, Devine SM. "Improved nonrelapse mortality and infection rate with lower dose of antithymocyte globulin in patients undergoing reduced-intensity conditioning allogeneic transplantationfor hematologic malignancies." Biol Blood Marrow Transplant. Vol. 15, no. 11. (November 2009.): 1422-1430.
Copelan E; Crilley P; Szer J; Dodds A; Stevenson D; Philips G; Elder P; Nivison-Smith I; Avalos B; Penza S; Topolsky D; Sobecks R; Kalaycio M; Bolwell B. "Late Mortality and Relapse Following BuCy2 and HLA-Identical Sibling Marrow Transplantation for Chronic Myeloid Leukemia." Biology of Blood and Marrow Transplantation. Vol. 15, no. 7. (July 2009.): 851-855.
Pant S, Hamadani M, Dodds AJ, Szer J, Crilley PA, Stevenson D, Phillips G, Elder P, Nivision-Smith I, Avalos BR, Penza S, Topolsky d, Sobecks R, Kalaycio M, Bolwell BJ, Copelan EA. "Incidence and reasons for late failure after allogeneic haematopoietic cell transplantation following BuCy2 in acute myeloid leukaemia." Br J Haematol. Vol. 148, no. 4. (February 2010.): 623-626.
Hamadani M, Craig M, Phillips GS, Abraham J, Tse W, Cumpston A, Gibson L, Remick SC, Bunner P, Leadmon S, Elder P, Hofmeister C, Penza S, Efebera Y, Andritsos L, Garzon R, Benson DM Jr, Blum W, Devine SM. "Higher busulfan dose intensity does not improve outcomes of patients undergoing allogeneic haematopoietic cell transplantation following fludarabine, busulfan-based reduced toxicity conditioning." Hematol Oncol. Vol. 29, no. 4. (December 2011.): 202-210.
Dunavin NC, Wei L, Elder P, Phillips GS, Benson DM Jr, Hofmeister CC, Penza S, Greenfield C, Rose KS, Rieser G, Merritt L, Ketcham J, Heerema N, Byrd JC, Devine SM, Efebera YA. "Early versus delayed autologous stem cell transplantation in patients receiving novel therapies for Multiple Myeloma." Leuk Lymphoma. Vol. Epub ahead of print, (November 2012.): .-.
Cohen, Jonathon, Jones, Jeffrey; Porcu, Pierluigi; Baiocchi, Robert; Penza, Sam; Benson, Don; Flynn, Joseph; Andritsos, Leslie. "Association of Pre-Transplantation PET/CT and Outcome in Mantle Cell Lymphoma." BMT. -.
|January 1995||Copelan E, Avalos BR, Elder PJ, Ezzone SA, Scholl MD, Bechtel TP, Belt PK, Hehmeyer DM, Penza SL."Development of GVHD as associated with improved outcome following marrow transplantation for advance leukemia" .. : 397a|
|January 1995||Copelan E, Ceselski S, Lasky L, Ezzone S, Bechtel T, Klein J, Marshall D, Wani B, Elder P, Penza S, Young D, Avalos BR."Mobilization of peripheral blood progenitor cells using etoposide and G-CFT" .. : 982a|
|January 1996||Copelan E, Penza S, Sholl D, Ezzone S, Elder P, Avalos BR."Results using early autologous and allogeneic bone marrow transplantation in patients with indolent lymphoma" .. : 618a|
|January 1996||Copelan E, Biggs JC, Szer J, Crilley P, Atkinson K, Avalos B, Topolsky D, Penza SL, Elder PJ, Bulova SI, Brodsky I."Treatment of Chronic Myelogenous Leukemia (CML) with allogeneic bone marrow transplantation after preparation with BuCy2" New York. : 670a|
|January 1997||Copelan EA, Penza SL, Elder PJ, Bechtel TP, Belt PS, Hehmeyer DM, Ezzone SA, Avalos BR."Extended follow up on patient with chronic myelogenous leukemia undergoing allogeneic transplantation following preparation with busulfan and cyclophosphamide" .. : 25a|
|January 1997||Copelan EA, Penza S, Ezzone S, Elder P, Hehmeyer D, Bechtel T, Avalos BR."Low dose, short course cyclosporine as a single agent for prevention of GVHD in patients with advanced leukemia" .. : 227 B|
|January 1998||Copelan E, Penza S, Theil K, Tighe MB, Elder P, Bechtel T, Belt P, Young D, Avalos BR."Allogeneic marrow transplantation with BuCy2 in patients with chronic myelogenous leukemia" .. : 285 a|
|June 1998||Moss TJ, Penza S, Pecora AL, Preti R, Weaver C, Buckner D, Copelan E."Increased tumor contamination with increasing the number of phereses for stage IV breast cancer" New Rochelle.|
|January 1998||Copelan E, Penza S, Pohlman B, Avalos BR, Goormastic M, Andresen S, Kalayico M, Tighe MB, Elder P, O'Donnell L, Bechtel T, Young D, Bolwell B."A novel Bu/Cy/VP-16 regimen in non-Hodgkin's lymphoma" .. : 664 a|
|January 1999||Copelan EA, Penza SL, Elder PJ, O'Donnell LC, Scholl MD, Ezzone SA, Risley GL, Bechtel TP, Avalos BR."Analysis of factors predicting speed of hematopoietic recovery using projenitor cells moblized with etoposide and G-CSF" .. : 140 a|
|January 1999||Copelan EA, Penza SL, Elder PJ, Ezzone SA, Scholl MD, Bechtel TP, Belt PS, Avalos BR."Analysis of prognostic factors for allogeneinic marrow transplantation following BuCy2 in myelodysplastic syndrome" .. : 661 a|
|January 1999||Copelan EA, Penza SL, Bechtel TP, Elder PJ, Avalos BR."Busulfan levels are influenced by prior treatment and are associated with VOD and early mortality but not with late complications, replase, or sustained survival" .. : 335 a|
|January 1999||Copelan E, Penza S, Pohlman B, Avalos BR, Goormastic, Andresen S, Kalaycio M, Elder P, Bechtel T, Scholl MD, Ezzone S, O'Donnell L, Risely G, Bolwell B."Phase II study of novel busulfan-etopside-cyclophosphamide regimen in Hodgkin's disease and analysis of prognostic factors" .. : 169a|
|November 1999||Levine JE, Penza S, Topolsky D, Beatty P, Rifkin R, Giralt S, Porter DL, Drobyski WR, Horowitz MM, Collins RH."Prospective trial of chemotherapy plus donor leukocyte infusion s (DLI) to treat relapsed advanced myeloid leukemia after related bone marrow transplantation (BMT)" Washington, DC. : 668a|
|January 2000||Farag SS, Elder PJ, Marcucci G, Penza S, Avalos B, Copelan E."Allogeneic hematopoietic cell transplantation in patients aged 50 years and over using conditioning regimens not containing total body irradiation (TBI)" .. : 408a|
|January 2000||Penza SL, Avalos BR, Elder PJ, Fike S, Farag SS, Marcucci G, O'Donnell LC, Scholl MD, Whittaker B, Mrozek E, Bechtel TP, Copelan EA."Predictivie value of immunoctyochemical detection of breast cancer cells and other factors in autotransplantation for breast cancer" .. : 424 a|
|January 2000||Copelan EA, Penza SL, Elder PJ, Marcucci G, Farag SS, O'Donnell LC, Mrozek E, Fike S, Bechtel TP, Ezzone SA, Scholl MD, Avalos BR."Therapy-related myelodysplasia and AML occur infrequently following etoposdie moblization and autologous stem cell transplantation using radation-free preparation" .. : 402 a|
|January 2000||Copelan EA, Morezek E, Penza SL, Elder PJ, Farag SS, Marcucci G, Bechtel TP, Avalos BR."Delayed development of pulmonary toxicity syndrome following busulfan preparative therapy for allogeneic marrow transplantation in multiple myeloma" .. : 354b|
|November 2000||Farag SS, Elder PJ, Marcucci G, Penza S, Avalos B, Copelan E."Radiation-free regimens produce similar outcomes in older vs younger patients undergoing allogeneic hematopoietic cell transplants (alloHCT)" Washington, DC. : 354b|
|November 2000||Farag S, Fike S, Elder P, Marcucci G, Penza S, Morozek E, Avalos B, Copelan E."Autologous and Allogeneic hematopoietic stem cell transplantation in multiple myeloma: A single institution experience" Washington, DC. : 354b|
|January 2000||Copelan EA, Mzrozek E, Penza SL, Elder PJ, Farag SS, Marcucci G, Bechtel TP, Avalos BR."Delayed development of pulmonary toxicity syndrome following busulfan preparative therapy for allogeneic marrow transplantation" .. : 408 a|
|January 2001||Copelan E, Kalayica M, Penza S, Pohlman B, Avalos B, Sobecks R, Farag S, Andersen S, Molina A, Kuczkowski E,."Results of a comparative trial of BuCyVP16 and BuCy2 as preparation for allogeneic transplantation in adults with advanced lymphohematopoietic malignancies" .. : 678 a|
|January 2001||Copelan E, Avalos B, Pohlman B, Penza S, Kalaycio M, Sobecks R, Farag S, Andersen S, Molina A, Kuczkowski E, Lin T, Marcucci G, Eler P, O'Donnell, Porcu P, Mrozek E, Bolwell B."Delay of transplantation beyond first relapse of low grade NHL adversely influences outcome" .. : 482a|
|January 2002||Farag S, Bolwell B, Elder P, Penza S, Kalaycia M, Avalos B, Pohlman B, Marcucci G, Molina A, Sobecks R, Lin T, Andersen S, Copelan E."Long-term outcome of hodgkin's disease in patients following high dose busulfan, etoposide, cyclophossphamide and autologous stem cell transplantation" .. : 863 a|
|January 2002||Copelan E,. Crilley P, Kalaycio M, Andersen S, Avalos B, Brodsky I, Elder P, Farag S, Gladstone D, Lin T, Molina A, Penza S, Pohlman B, Sobecks R, Styler M, Topolsky D, Bolwell B."Is a delay in Transplantation of older individuals with CML a self-fulfilling prophecy" ..|
|January 2002||Lin TS, Molina A, Penza SL, Farag SS, Avolos BR, Grever MR, Copelan EA, Byrd JC.."Diffuse Alveolar Hemorrhage in Patients Undergoing Non-Myeloablative Allogeneic Stem Cell Transplantation after Prior Autologous/Syngeneic Transplantation" .. : 378 B|
|January 2002||Lin ST, Elder PJ, Penza SL, Avalos BR, Farag SS, Molina A, Mrozek E, Belt PS, Porcu P, Marcucci G, Byrd JC, Copelan EA."Autologous stem cell transplants results in better 5-year overall, but not progression-free survival than allogeneic transplants in patients with indolent Non-Hodgkin's lymphoma" .. : 863 a|
|January 2003||Lin TS, Elder PJ, Penza SL, Avalos BR, Farag SS, Copelan EA."Single Institution Experience with Non-Myeloablative Allogeneic Stem Cell Transplant Conditioning Regimen Using Fludarabine and Total Body Irradiation" .. : 730|
|January 2003||Copelan E, Penza S, Lin T, Farag S, Blum W, Elder P, Ezzone S, Avalos B."Matched unrelated transplantation in older individuals" ..|
|January 2003||Copelan E, Penza S, Lin T, Farag S, Blum W, Elder P, Ezzone S, Avalos B."Result of Allogeneic Transplantation Using Fully Myeloablative Preparation in Patients Who are Candidates for Reduced Intensity Regimens" ..|
|January 2003||Blum W.G, Bolwell BJ, Farag SS. Lin TS, Avalos BR, Penza SL, Marcucci G, Byrd JC, Kalaycio ME, Sobecks RM, Pohlman B, Brown S, Elder PJ, Copelan EA."Only Those Refractory AML Patients with Low Disease Burden Can Achieve Prolonged Leukemia-Free Survival with Conventional Unrelated Donor Transplantation" .. : 488 a|
|January 2004||Blum W, Penza S, Farag S, Avalos B, Marcucci G, Lin T, Byrd J, Elder P, Copelan E."Incidence of Extramedullary Relapses of Acute Myeloid Leukemia Following Transplantation with Busulfan-Based Conditioning Regimens" .. : 364 a|
|January 2004||Benson D, Elder P, Lin T, Blum B, Penza S, Avalos B, Byrd J, Copelan E, Farag S."Single Institution Experience with Two High-Dose Chemotherapy (HDC) Conditioning Regimens Prior to Autologous Stem Cell Transplant (ASCT) for Multiple Myeloma (MM)" .. : 388 a|
|June 2005||Griffith N, Pultz A, Moleski R, Reitan J, Miklovich G, Penza S, Allen C."Impact of a Long-Acting Erythropoietic Growth Factor on Practice Dynamics in an Oncology Clinic" Boston.|
|March 2006||Allen C, Griffith N, Penza S."Oral Chemotherapy in the Ambulatory Environment: Compliance and Economic Issues" Columbus.|
|January 2008||Hafford A, Griffith N, Penza S, Seoane-Vazquez E."A Retrospective Evaluation of a Pharmacist-Directed Anemia Management Program" Columbus.|
|February 2008||Bechtel TP, Crawford BS, Gordon SM, Penza S, Hofmeister CC, Benson D, Devine S."Biology of Blood and Marrow Transplantation" .. : 166|
|June 2008||Poi M, Penza S, Griffith N, Mazzamuto A, Blazer M, McPherson E."Development of a Clinical Tool for Pharmacist-Driven Chemotherapy-Induced Nausea and Vomiting Management" Anaheim.|
|June 2008||Griffith N, McPeek J, Turowski R, Saab T, Penza S."Development and Implementation of an Off-Label Medication Use Policy at the Comprehensive Cancer Center" Anaheim.|
|November 2008||Pant S, Hamadani M, Crilley P, Szer J, Dodds A, Stevenson D, Phillips G, Elder P, Nivison-Smith I, Avalos B, Penza S, Topolsky D, Sobecks R, Kalaycio M, Bolwell B, Copelan E."Incidence of late failure following myeloablative conditioning with BuCy2 and matched sibling allogeneic stem cell transplantation for acute myeloid leukemia" Washington, DC. : Abstract 2172|
|January 2008||Hamadani M, Blum W, Benson D, Blum KA, Porcu P, Elder P, Krugh D, Andritisos LA, Garzon R, Penza S, Thomas SL."Assessment of Rabbit Antithymocyte Globulin (rATG) Dose-Intensity in Patients with Hematological Malignancies Undergoing Allogeneic Stem Cell Transplantation (ASCT) Following Reduced Intensity Conditioning (RIC) with Fludarabine, Busulfan and rATG (FBA)" .. : 4405|
|November 2008||Copelan E, Crilley P, Szer J, Dodds A, Avalos B, Penza S, Topolsky D, Sobecks R, Kalaycio M, Bolwell B."Late mortality and relapse following HLA-idendical sibling donor marrow transplantation for chronic myeloid leukemia" Washington, DC. : abstract #3264|
|February 2009||Benson D, Hofmeister CC, Hamadani M, Panzner K, Smith M, Penza S, Elder P, Krugh D, O’Donnell L, Devine D."Pre-mobilization bone marrow plasmacytosis predicts successful stem cell mobilization in patients with multiple myeloma receiving lenalidomide-based induction regimens" ,.|
|November 2011||Cohen JB, Hall N, Ruppert AS, Jones JA, Porcu P, Baiocchi RA, Penza S, Benson DM, Andritsos LA, Flynn JM, Devine SM, Blum KA."The prognostic value of FDG PET/CT prior to autologous stemm cell transplant in mantle cell lymphoma" Washington, DC.|
|February 2012||Salem G, Ruppert AS, Efebera Y, Elder P, Bingman A, Penza S, Andritsos LA, Devine SM."Busulfan, cyclophosphamide, etoposide (BUCYVP) or carmustine, etoposide, cytarabine, melphelan (BEAM) for conditioning prior to autologous stem cell transplantation (ASCT) in patients with Hodgkin Lymphoma (HL)" New York. : abstract #115|
|April 2012||Salem G, Dunavin N, Wei L, Elder E, Penza S, Blum K, Porcu P, Baiocchi R, Jones JA, Flynn J, Andritsos L, Devine SM, Christian B, Efebera Y."Busulfan, cyclophosphamide, etoposide is not superior to carmustine, etoposide, cytarabine, mephalan conditioning prior to autologous stem cell transplantation in patients with Hodkin's lymphoma and is associated with increased toxicity" Barcelona.|
|Hofmeister CC, Bowers MA, Baiocchi RA, Lozanski G, Humphries K, Blum KA, Porcu P, Penza S, Andritsos LA, Devine SM."Post autologous transplant vorinostat (SAHA) in high risk lymphoma: Phase 1 study of vorinostat maintenance" .|
|January 2003||Sam Penza."Omen program"|
"Fungal Infections in Oncology Patient." Presented at City, Columbus. (October 2001)
"Fungal Infections in the Hospital." Gallipolis, OH. (March 2001)
"VFEND." Columbus, OH. (August 2002)
"Diflucan and VFEND Lecture." Wheeling, WV. (August 2002)
"Advances in Antifungal Therapy." Columbus, OH. (October 2002)
"Antifungal Treatment in High Risk Patients." Presented at Balancing Risk and Reward, Chicago, IL. (June 2002)
"Zyvox Pharmacia." Cleveland, OH. (September 2002)
"Advances in Antifungal Therapy." Pittsburgh, PA. (September 2002)
"Advances in Antifungal Therapy." Cleveland, OH. (September 2002)
"Roundtable Discussion." Presented at ., Houston. (December 2003)
"Anemia." Presented at Omen Telecast Presentation, Columbus. (January 2003)
"Anemia." Presented at Investigator Meeting, Boca Raton, FL. (February 2003)
"Infection Prophylaxis and Management." Presented at BMT Continuing Education Classes, Columbus, OH. (July 2003)
"Aranesp Lecture." Cincinnati, OH. (August 2003)
"Evolving Epidemiology of Fungal Infections." Barboursville, WV. (November 2003)
"Advances in Antifungal Therapy." Philadelphia, PA. (November 2003)
"Fungal Infections in BMT." Ann Arbor, MI. (September 2003)
"Systemic Fungal Infections." Columbus, OH. (October 2003)
"New Directions in Anemia Management." Springfield, OH. (October 2003)
"Consulting." Presented at Midwest Oncology Consulting, Palm Spring, FL. (October 2003)
"Fungal Experts Moderators meeting." Presented at Fungal Experts in the Nation, Houston. (July 2004)
"Fungal Infections Immunocompromised Hosts." Munster, IN. (July 2004)
"Evolving Epidemiology of Fungal Infections." Cincinnati, OH. (January 2004)
"Epidemiology of Fungal Infections." Presented at Veterans Association Lecture, Chillicothe. (May 2004)
"Evolving Epidemiology of Fungal Infections with a Special Focus on Candidemia." Presented at ., Cleveland. (August 2005)
"A Clinical Learning Experience." Presented at Grand Rounds, Indianapolis. (November 2005)
"Evolving Epidemiology of Fungal Infections with Special Focus on Candidemia." Cleveland, OH. (September 2005)
"Neutropenia Guideline Updates." Columbus, OH. (October 2005)
"An Empirical Approach to Antifungal Therapy in Presistant Febrile Neutropenia." Columbus, OH. (October 2005)
"Prevention of Febrile Neutropenia-NCCN Guideline for Growth Factors." Columbus, OH. (November 2005)
"Impact of a Long-Acting Erythropoeitic Growth Factor on Practice Dynamics in an Oncology Clinic." Presented at ASHP Annual Meeting, MA. (June 2005)
"Neutropenia Guideline Updates." Columbus, OH. (October 2006)
"New Paradigms in Oncology: Emerging Science on the Management of Chemotherapy induced anemias." Columbus, OH. (September 2006)
"Burden of Mucositis: Physician." Dayton, OH. (December 2006)
"Oral Chemotherapy in the Ambulatory Environment: Compliance and Economic Issues." Presented at Cancer Care Across the Continuum: New Discoveries, New Modalities, . (March 2006)
"New Evidence for the Use of Neulasta in the First and Subsequent Cycle of Moderately Myelosuppresive Chemotherapy." Presented at ., Columbus. (May 2007)
"Invasive Fungal Infections in High Risk Patients." Covington, KY. (May 2007)
"Advancement in the Management of Invasive Fungal Infections in High Risk Patient." Columbus, OH. (April 2007)
"New Evidence for Use of Neulasta in First and Subsequent Cycles of Moderately Myelosuppresive Chemotherapy Regimens." Columbus, OH. (October 2007)
"ESAâ€™s New Class Label." Columbus, OH. (October 2007)
"Advancements in the Management of Invasive Fungal Infections in." Columbus, OH. (October 2007)
"Advancements in the Management of Invasive Fungal Infections In High Risk Patients." Columbus, OH. (December 2007)
"New Directions In Oncology: New Strategies for Managing Febrile Neutropenia." Presented at ., Columbus. (February 2008)
"Strategies for Minimizing Antimicrobial Resistance: Improving the Process." Columbus, OH. (September 2008)
"Strategies for Minimizing Antimicrobial Resistance: Improving the Process." Columbus, OH. (September 2008)
"Advancements in the Management of Invasive Fungal Infections in High Risk Patients." Columbus, OH. (September 2008)
"Clinical Progression of Leukemia." Columbus, OH. (April 2008)
"Helping to Achieve Optimal Outcomes in the Ongoing Battle Against Cancer." . (August 2008)
"Advancements in the Management of Invasive Fungal Infectiosn in High Risk Patients." . (January 2008)
"Development and Implementation of an Off Label Medication Use Policy at a Comprehensive Cancer Center." Presented at HOPA/ISOPP 2008 Annual Conference, Anaheim, CA. (June 2008)
"New Important Clinical Advances in the Management of Chemotherapy Induced Neutropenia." Lexington, KY. (June 2009)
"Helping to Achieve Optimal Outcomes in the Ongoing Battle Against Cancer." Chillicothe, OH. (June 2009)
"Helping to Achieve Optimal Outcomes in the Ongoing Battle Against Cancer." Lexington, KY. (June 2009)
"Healthcare Professionals." Columbus, OH. (June 2009)
"Update to Managing Anemia in Patients with Non Myeloid Malignancies Receiving Concomitant Chemotherapy." Troy, MI. (February 2009)
"Helping to Achieve Optimal Outcomes in the Ongoing Battle Against Cancer." Columbus, OH. (March 2009)
"Helping to Achieve Optimal Outcomes in the Ongoing Battle Against Cancer." Cincinnati, OH. (May 2009)
"Assessment of Medication-Related Information Received by Patients Regarding Their Oral Chemotherapy Medications." Presented at HOPA 2009 Annual Conference, FL. (June 2009)
"Presumed Fungal Infections in Persistently Febrile Neutropenic Patients." Columbus, OH. (January 2011)
"CRM Leadership Introduction." Presented at CRM Workshop, Columbus. (January 2011)
"Characterization of Febrile Neutropenia in Relation to Myeloid Growth Factor Utilization in Patients Receiving Chemotherapy Regimens with an Intermediate Risk for Febrile Neutropenia." Presented at HOPA 2011 Annual Conference, Utah. (March 2011)
|1998 - present||James Cancer Survivor Picnic. James. Columbus, OH.|
|2011 - present||James/Whittier Kickball Game. Westerville, OH.|
Caterino J, O'Brien J, Stevenson K, Penza S. Clinician's guide to sepsis and septic shock. 2 ed. : (September 2011).